Botulinum toxin type A therapy for blepharospasm

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 11, 2020, Pages

  Duarte, Gonçalo S ^a,b   Rodrigues, Filipe B ^a,b   Marques, Raquel E ^a,b   Castelão, Mafalda ^a,b   Ferreira, Joaquim ^a,b   Sampaio, Cristina ^c   Moore, Austen P ^d   Costa, João ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^c CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^d THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; MUSCLE RELAXANT AGENT;

BLEPHAROSPASM; BLURRED VISION; DIPLOPIA; DISABILITY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; HEAD AND NECK DISEASE; HEADACHE; HUMAN; INJECTION SITE PAIN; INVOLUNTARY MOVEMENT; LACRIMATION DISORDER; MALAISE; META ANALYSIS; MUSCLE WEAKNESS; NECK WEAKNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PTOSIS (EYELID); RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SIDE EFFECT; SORE THROAT; SYSTEMATIC REVIEW; VISUAL DISORDER; VOICE CHANGE; XEROPHTHALMIA; XEROSTOMIA; DOSE RESPONSE; FEMALE; MALE; STATISTICAL BIAS;

BIAS; BLEPHAROSPASM; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85096458616     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004900.pub3     Document Type: Review

References (106)

1. Brodsky M, Jankovic J, Evidente V, Fernandez H, Grafe S. IncobotulinumtoxinA (NT-201) injections are safe and effective in adult subjects with blepharospasm across dosing intervals in a repeated dose-study. Movement Disorders 2011;26(Suppl 2):S206. x-wiley/crsRef/3358516
2. Fernandez HH, Evidente VGH, Truong D, Brodsky M, HanschmannA, Comella CL, et al. Long-term treatment of blepharospasm and cervical dystonia: Incobotulinum toxin A is well tolerated when injected at flexible intervals based on patient needs. Journal of the Neurological Sciences 2013;333:e120. x-wiley/crsRef/3358514 [DOI: 10.1016/j.jns.2013.07.403]
3. Grafe S, Jankovic J, Hanschmann A. Efficacy and safety of NT 201 (botulinum neurotoxin type A free from complexing proteins) for the treatment of blepharospasm: results of a double-blind, placebo-controlled, randomized, multicenter trial. Physical Medicine and Rehabilitation 2010;2:S29-30. x-wiley/crsRef/3358517
4. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm – a randomized trial. Movement Disorders 2011;26(8):1521-8. x-wiley/crsRef/3358515 [DOI: 10.1002/mds23658]
5. Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez HH, Xeomin US Blepharospasm Study Group. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm. Journal of Neural Transmission 2013;120(9):1345–53. x-wiley/crsRef/3358513 [DOI: 10.1007/s00702-013-0998-9]
6. Mitsikostas DD, Dekundy A, Sternberg K, Pagan F. Safety and efficacy of incobotulinum toxin A for the treatment of blepharospasm in botulinum toxin-naive subjects. Neurology 2018;90(Suppl 15):P5.041. x-wiley/crsRef/14749106
7. NCT01896895. Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid [Prospective, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of Two Different Doses of NT 201 in Botulinum Toxin Treatment-naïve Subjects With Blepharospasm]. clinicaltrials.gov/show/NCT01896895 (first received 11 Jully 2013). x-wiley/crsRef/14749107
8. Truong D, Comella C, Fernandez HH, Ondo WG, Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism and Related Disorders 2008;14(5):407-14. x-wiley/crsRef/3358519 [10.1016/j.parkreldis.2007.11.003]
9. Aramideh M, Ongerboer de Visser BW, Brans JW, Koelman JH, Speelman JD. Pretarsal application of botulinum toxin for treatment of blepharospasm. Journal of Neurology, Neurosurgery and Psychiatry 1995;59(3):309-11. x-wiley/crsRef/3358521
10. Boyle M, McGwin M, Flanagan C, Vicinanzo M, Long J. High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference? Ophthalmic Plastic and Reconstructive Surgery 2009;25(2):81-4. x-wiley/crsRef/3358523
11. Fahn S, List T, Moslowitz C, Brin M, Bressman S, Burke R, Scott A. Double-blind controlled study of botulinum toxin for blepharospasm. Neurology 1985;35(Suppl 1):271-2. x-wiley/crsRef/3358525
12. Frueh BR, Nelson CC, Kapustiak JF, Mush DC. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. American Journal of Ophthalmology 1988;106:45-7. x-wiley/crsRef/3358527
13. Girlanda P, Quartarone A, Sinicropi S, Nicolosi C, Messina C. Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study. Movement Disorders 1996;11(1):27-31. x-wiley/crsRef/3358529
14. Iwashige H, Nemoto Y, Takahashi H, Maruo T. Botulinum toxin type A (Botox) for treatment of blepharospasm: an open label, dose response study. Nihon Ganka Gakkai Zasshi 1995;99(6):663-8. x-wiley/crsRef/3358531
15. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37:616-23. x-wiley/crsRef/3358533
16. Jankovic J. Blepharospasm and oromandibular-laryngeal cervical dystonia: a controlled trial of botulinum A toxin therapy. Advances in Neurology 1988;50:583-591. x-wiley/crsRef/3358534
17. Jankovic J. Apraxia of lid opening. Movement Disorders 1995;10(5):686-7. x-wiley/crsRef/3358536
18. Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. Journal of Neurology, Neurosurgery and Psychiatry 1996;60(6):704. x-wiley/crsRef/3358537
19. Mezaki T, Kaji R, Kohara N, Fujii H, Katayama M, Shimizu T, et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 1995;45(3 Pt 1):506-8. x-wiley/crsRef/3358539
20. Mezaki T, Kaji R, Brin MF, Hirota-Katayama M, Kubori T, Shimizu T, et al. Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial. Movement Disorders 1999;14(6):1017-20. x-wiley/crsRef/3358541
21. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Archives of Clinical and Experimental Ophthalmology 1997;235(4):197-9. x-wiley/crsRef/3358543
22. Park YC, Lim JK, Lee DK, Doe Yi S. Botulinum A toxin treatment of hemifacial spasm and blepharospasm. Journal of Korean Medical Science 1993;8(5):334-40. x-wiley/crsRef/3358545
23. Price J, Farish S, Taylor H, O'Day J. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology 1997;104(5):865-8. x-wiley/crsRef/3358547
24. Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhães M, Martins R, et al. DYSBOT: a single blind, randomized clinical trial to compare two different formulations of botulinum toxin type A. Movement Disorders 1995;10(3):387. x-wiley/crsRef/3358550
25. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A – Dysport and Botox – assuming a ratio of 4:1. Movement Disorders 1997;12(6):1013-8. x-wiley/crsRef/3358551
26. Abrams KR, Gillies CL, Lambert PC. Meta-analysis of heterogeneously reported trials assessing change from baseline. Statistics in Medicine 2005;24:3823-44.
27. Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. European Journal of Neurology 2011;18:5-18.
28. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders 2013;28(7):863-73.
29. Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Medical Research Methodology 2002;2:3.
30. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin. Journal of Neuroscience 2008;28:3689–96.
31. Aramideh M, Ongerboer de Visser BW, Devriese PP, Bour LJ, Speelman JD. Electromyographic features of levator palpebrae superioris and orbicularis oculi muscles in blepharospasm. Brain 1994;117:27-38.
32. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6.
33. Berardelli A, Rothwell JC, Day BL, Maesden CD. Pathophysiology of blepharospasm and oromandibular dystonia. Brain 1985;108:593-608.
34. Boroff DA, Chen GS. On the question of permeability of the blood–brain barrier to botulinum toxin. International Archives of Allergy and Applied Immunology 1975;48:495–504.
35. Brożek JL, Guyatt GH, Schünemann HJ. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health and Quality of Life Outcomes 2006;4:69.
36. Cardoso F, Jankovic J. Blepharospasm. In: Handbook of Dystonia. Tsui J, Calne D edition. New York: Marcel Dekker, 1995:129-42.
37. Carpenter J, Kenward M. Multiple Imputation and its Application. 1st edition. John Wiley & Sons, 2013.
38. Carrasco-Labra A, Brignardello-Petersen R, Santesso N, Neumann I, Mustafa RA, Mbuagbaw L, et al. Improving GRADE evidence tables part 1: a randomized trial shows improved understanding of content in summary of findings tables with a new format. Journal of clinical epidemiology 2016;74:7-18. [PMID: 26791430]
39. Castelão M, Marques RE, Duarte GS, Rodrigues FB, Ferreira J, Sampaio C, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No: CD003633. [DOI: 10.1002/14651858.CD003633.pub3]
40. Cohen J. Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc., 1988.
41. Corbett MS, Higgins JP, Woolacott NF. Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods 2014;5(1):79-85.
42. Costa J, Espírito-Santo CC, Borges AA, Ferreira J, Coelho MM, Moore P, et al. Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database of Systematic Reviews 2005;(1).
43. de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proceedings of the National Academy of Sciences of the United States of America 1999;96:3200–5.
44. Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.training.cochrane.org/handbook.
45. Duarte GS, Castelão M, Rodrigues FB, Marques RE, Ferreira J, Sampaio C, et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No: CD004314. [DOI: 10.1002/14651858.CD004314.pub3]
46. Duarte GD, Rodrigues FB, Ferreira JJ, Costa J. Adverse events with botulinum toxin treatment in cervical dystonia: how much should we blame placebo? Parkinsonism & Related Disorders 2018;56:16-9. [DOI: 10.1016/j.parkreldis.2018.06.017]
47. Duchen LW. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. Journal of the Neurological Sciences 1971;14(1):47-60.
48. Elston JS, Marsden CD, Grandas F, Quinn NT. The significance of ophthalmological symptoms in idiopathic blepharospasm. Eye 1988;2:435-9.
49. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Oto-laryngologica 1993;113:400–4.
50. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45:769-73.
51. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics: Targets & Therapy 2010 Dec;4:325-32.
52. Frueh BR, Callahan A, Dortzbach RK, Wilkins RB, Beale HL, Reitman HS, et al. A profile of patients with intractable blepharospasm. Transactions of the American Academy of Ophthalmology and Otolaryngology 1976;81(4 Pt 1):OP591-4.
53. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10.
54. McMaster University (developed by Evidence Prime) GRADEpro GDT. Version accessed 3 January 2017. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
55. Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. Journal of Neurology, Neurosurgery and Psychiatry 1988;51:767-72.
56. Grandas F, Traba A, Alonso F, Esteban A. Blink reflex recovery cycle in patients with blepharospasm unilaterally treated with botulinum toxin. Clinical Neuropharmacology 1998;21(5):307-11.
57. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.
58. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, California: Academic Press, Inc, 1985.
59. Henderson JW. Essential blepharospasm. Transactions of the American Academy of Ophthalmology Society 1956;54:453-520.
60. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
61. Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.training.cochrane.org/handbook.
62. Higgins JPT, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.training.cochrane.org/handbook.
63. Higgins JPT, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.training.cochrane.org/handbook.
64. Holland RL, Brown MC. Nerve growth in botulinum toxin poisoned muscles. Neuroscience 1981;6:1167–79.
65. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double blind crossover study. Annals of Neurology 1982;11:41-7.
66. Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm. Journal of the American Medical Association 1982;248:3160-4.
67. Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacology findings in 100 patients. Annals of Neurology 1983;13:402-11.
68. Jankovic J. Botulinum toxin in clinical practice. Journal of Neurology, Neurosurgery, and Psychiatry 2004;75(7):951-7.
69. Juzans P, Comella J, Molgo J, Faille L, Angaut-Petit D. Nerve terminal sprouting inbotulinum type-A treated mouse levator auris longus muscle. Neuromuscular Disorders: NMD 1996;6(3):177-85.
70. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6:e1000100.
71. Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, et al. Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs). Trials 2014;15:49.
72. Marques RE, Duarte GS, Rodrigues FB, Castelão M, Ferreira J, Sampaio C et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No: CD004315. [DOI: 10.1002/14651858.CD004315.pub3] [PMID: 27176573]
73. Marsden CD. Blepharospasm-oromandimular dystonia syndrome. Journal of Neurology, Neurosurgery and Psychiatry 1976;390:1204-9.
74. Matak I, Lacković Z. Botulinum toxin A, brain and pain. Progress in Neurobiology 2014 Aug-Sep;119-120:39–59.
75. Matak I, Lacković Z. Botulinum neurotoxin type A: actions beyond SNAP-25? Toxicology 2015;335:79-84.
76. Nutt JG, Muenter MD, Melton LJ 3rd, Aronson A, Kurland LT. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Movement Disorders 1988;3(3):188-94.
77. Palomar FJ, Mir P. Neurophysiological changes after intramuscular injection of botulinum toxin. Clinical Neurophysiology 2012;123:23:54–60.
78. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1999;354:259–68.
79. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. Journal of the American Medical Association 2006;295(6):676-80.
80. Rato ML, Duarte GS, Mestre T, de Carvalho M, Ferreira JJ. Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. Lancet Neurology 2018;17(10):842. [DOI: 10.1016/S1474-4422(18)30310-7]
81. Rato ML, Duarte GS, Ferreira AN, Alves M, Mainoli B, Teodoro T, et al. Nocebo response in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism & Related Disorders 2019;65:13-9. [DOI: 10.1016/j.parkreldis.2019.04.015]
82. Nordic Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Centre, The Cochrane Collaboration, 2014.
83. Rosales RL, Arimura K, Takenaka S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle & Nerve 1996;19:488–96.
84. Rosales RL, Dressler D. On muscle spindles, dystonia and botulinum toxin. European Journal of Neurology 2010;17:71–80.
85. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Statistics in Medicine 1991;10:585–98.
86. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.training.cochrane.org/handbook.
87. Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D, et al. Placebo and nocebo responses in restless legs syndrome: a systematic review and meta-analysis. Neurology 2017;88(23):2216-24. [DOI: 10.1212/WNL.0000000000004004]
88. Simpson LL. Identification of the major steps in botulinum toxin action. Annual Review of Pharmacology and Toxicology 2004;44:167-93.
89. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016;10:1818-26.
90. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analysis – sometimes informative, usually misleading. BMJ 1999;318(7197):1548-51.
91. Stata. Version 15. College Station, TX, USA: StataCorp., 2017. Available from www.stata.com.
92. Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Movement Disorders 2012;27(14):1789-96.
93. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. Journal of Clinical Epidemiology 2001;54(10):1046-55.
94. Sterne JAC, Egger M, Moher D, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.training.cochrane.org/handbook 2011.
95. Tarsy D, Simon DK. Dystonia. New England Journal of Medicine 2006;355:818-29.
96. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa ̇manual.pdf 2011.
97. Tolosa ES, Klawans HL. Meige's disease: a clinical form of a facial convulsion, bilateral and medial. Archives of Neurology 1979;36:635-7.
98. Tolosa ES. Clinical features of Meige's disease (idiopathic orofacial dystonia): a report of 17 cases. Archives of Neurology 1981;36:147-51.
99. Tolosa E, Marti MJ. Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects. Advances in Neurology 1988:73-84.
100. Copenhagen Trial Unit Trial Sequential Analysis. Version 0.9 Beta. Copenhagen Trial Unit, Version accessed 3 January 2017. Copenhagen: Copenhagen Trial Unit, 2011. Available at www.ctu.dk/tsa/downloads.aspx.
101. Tucha O, Naumann M, Berg D, Alders GL, Lange KW. Quality of life in patients with blepharospasm. Acta Neurologica Scandinavica 2001;103(1):49-52.
102. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38.
103. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. Journal of Clinical and Aesthetic Dermatology 2014;7(2):31-9.
104. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a lack of standardization in methods for handling missing variance data. Journal of Clinical Epidemiology 2006;59(4):342-53.
105. Zoons E, Dijkgraaf MGW, Dijk JM, vVan Schaik IN, Tijssen MA. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. Neurology 2012;259(12):2519–26.
106. Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No: CD004900. [DOI: 10.1002/14651858.CD004900.pub2]